



## **SARS-CoV-2 Serological Studies around the World**

Guest Editors:

**Dr. Julien Mélade**

**Dr. Paola Mariela Saba  
Villarroel**

**Dr. François Meurens**

Deadline for manuscript  
submissions:  
**closed (20 October 2023)**

### **Message from the Guest Editors**

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, a severe pneumonia leading to respiratory distress, has now spread around the world with more than 615 million people being infected.

During the course of the pandemic, several variants carrying amino acid changes in the entire genome of SARS-CoV-2 emerged worldwide. The emergence of these variants was often accompanied by a loss of effectiveness of immune efficiency, induced by primary infection, vaccination or therapeutic treatments.

The need for serological investigation to analyze the antibody responses, titer and duration elicited by primary infection or vaccination against the circulating variants will greatly help the identification of the populations at risk of re-infection and will help monitor the efficacy of COVID-19 vaccines, thus, accelerating the public health policy decision.

For this Special Issue, both reviews and research articles describing the SARS-CoV-2 sero-epidemiology using robust system or gold standard tools will be welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)